<DOC>
	<DOCNO>NCT02404922</DOCNO>
	<brief_summary>This study assess healthy male female subject safety , tolerability pharmacokinetics ( PK ) profile Immediate Release CTP-730 steady state follow 7 day dose . Three dos Immediate Release ( IR ) CTP-730 capsule study .</brief_summary>
	<brief_title>Multiple Ascending Dose Study Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy adult male females 18 50 year age . Body weight ≥ 50 kg BMI within range 18 30 kg/m2 Medical , psychiatric illness history depression could , investigator 's opinion , compromise subject 's safety Significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study . History clinically significant central nervous system ( eg , seizure ) , cardiac , pulmonary , metabolic , renal , hepatic , gastrointestinal ( GI ) condition . PR interval ≥ 220 msec QRS duration ≥ 120 msec QTcB / QTcF interval &gt; 450 msec obtain screen visit prior first dose study drug . Liver function test great upper limit normal . Positive blood screen human immunodeficiency virus ( HIV antibody ) , hepatitis B virus surface antigen , hepatitis C virus antibody screen . Urinalysis positive protein glucose . A positive screen alcohol , drug abuse , tobacco use . Inability comply food beverage restriction study participation . Donation blood collection acute loss blood prior screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Safety/Efficacy Study</keyword>
	<keyword>Randomized</keyword>
	<keyword>Double Blind</keyword>
</DOC>